Global /China /Healthcare /Biotechnology /000403

Pacific Shuanglin Bio-pharmacy Co., Ltd.

000403

• SHE: 000403 • Delayed

11.95CNY -1.8%

1.77 USD

As of 14 June 2026, Pacific Shuanglin Bio-pharmacy Co., Ltd. has a market cap of $1.71B USD, ranking #7798 globally and #1972 in China. It ranks #645 in the Healthcare sector, and #123 in the Biotechnology industry.

Global Rank

7798

Country Rank

1972

Sector Rank

645

Industry Rank

123

Key Stats

Market Cap

$1.71BUSD

11.57B CNY

Enterprise Value

$1.72BUSD

11.65B CNY

Revenue (TTM)

$383.84MUSD

2.6B CNY

EBITDA (TTM)

$97.16MUSD

657.53M CNY

Net Income (TTM)

$52.12MUSD

353.15M CNY

EBITDA Margin

25%

Profit Margin

14%

PE Ratio

34.2

Forward PE

11.5

PS Ratio

4.4

PB Ratio

1.4

EV/EBITDA

17.6

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Xiankui Rong open_in_new

Employees

2,635

Founded

1993

Website

slbiop.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.8%	-4.9%	-7.2%	-12%	-24%	-11%	-27%	-33%	-59%

News

Markets

Exchange	Ticker	Price	Quotes
Shenzhen Stock Exchange (SHE / SZSE) MIC: XSHE PRIMARY	000403 派斯双林生物制药股份有限公司 Class A ISIN: CNE000000F14 Shares Out.: Shares Outstanding: 950.397M¹ Shares Float: 536.8M² TV: TradingView: SZSE: 000403 SA: Stock Analysis: SHE: 000403 YF: Yahoo Finance: 000403.SZ GF: Google Finance: SHE: 000403 BA: Barron's: 000403 MS: Morningstar: XSHE: 000403	11.95 CNY	TV: TradingView: SZSE: 000403 SA: Stock Analysis: SHE: 000403 YF: Yahoo Finance: 000403.SZ GF: Google Finance: SHE: 000403 BA: Barron's: 000403 MS: Morningstar: XSHE: 000403

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Pacific Shuanglin Bio-pharmacy Co., Ltd.

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in research, development, production, and sales of blood products in China and internationally. The company offers human serum albumin, intravenous human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus and anti-tetanus human immunoglobulin, rabies patient immunoglobulin, human coagulation factor VIII, and human prothrombin complex; and freeze-dried intravenous human immunoglobulin (pH4), human fibrinogen, and intravenous hepatitis B human immunoglobulin (pH4). In addition, it engages in the investment, consultation, and technology promotion of pharmaceutical and biotechnology development projects; electronic product information consultation; trading; technology application; and technical services activities. The company was formerly known as Southern Shuanglin Bio-pharmacy Co., Ltd. and changed its name to Pacific Shuanglin Bio-pharmacy Co., Ltd. in April 2021. Pacific Shuanglin Bio-pharmacy Co., Ltd. was founded in 1993 and is headquartered in Taiyuan, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.44B 136.71B HKD 922%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 614%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.0B 54.23B CNY 369%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.33B 49.69B CNY 330%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 315%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.72B 45.52B CNY 294%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 11K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 9K%	19.0	United States
argenx SE EBR: ARGX	$47.84B 41.39B EUR 3K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.84B 68.19T KRW 3K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.36B 60.27B AUD 2K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.3B 33.71B CHF 2K%	37.2	Switzerland

chevron_leftBack